Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds

Alex C. Spyropoulos, Bríain Hartaigh, Zhun Cao, Harjeet Caberwal, Craig Lipkin, Michaela Petrini, Cheng Wang

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds'. Together they form a unique fingerprint.

Medicine & Life Sciences